Please assess the completion status of the following clinical trial:

Trial Title: The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active rheumatoid arthritis based on DAS28 score. Patients received the standard therapy (i.e. one or more conventional DMARDs) for at least three months.~Exclusion Criteria:~* Known hypersensitivity to metformin.~* Patients who have a prior diagnosis with diabetes mellitus.~* Patients receive metformin for any other indications.~* Patients with congestive heart failure.~* Patients with a history of myocardial infarction.~* Patients with severe anemia.~* Patients with active infections or other inflammatory diseases.~* Patients receiving biological therapy.~* Pregnancy or lactation.~* Patients with impaired liver functions.~* Patients with impaired kidney functions (serum creatinine concentrations ≥1.5 and ≥1.4 mg/dL in males and females respectively).~* Patients with malignancies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): patients will receive the standard therapy (methotrexate) plus placebo tablets
- Metformin group (Type: EXPERIMENTAL): patients will receive the standard therapy plus 1 g metformin daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).